Merck’s PD-1 Inhibitor Pembrolizumab Subcutaneous Injection Approved in China

Merck, a pharmaceutical company based in Kenilworth, New Jersey, announced that its PD-1 inhibitor pembrolizumab subcutaneous injection has been approved by the National Medical Products Administration (NMPA) in China. The approval covers 19 solid tumor indications, making it the first and currently only approved subcutaneous injection form of a PD-1 inhibitor in China. This approval is based on the research data of MK-3475A-D77. Dr. Li Zhengqing, Global Senior Vice President of Merck and President of Merck’s China Research Center, stated that “As an important product in Merck’s oncology portfolio, Keytruda® (pembrolizumab) continues to expand its indications and accumulate clinical evidence…